Zeposia’s Ulcerative Colitis Approval Provides BMS’s Beachhead Into GI

The second US approval for the S1P receptor agonist brings Bristol into the gastrointestinal space, and is just the starting point for the pharma in that arena, the company told Scrip.

FDA approved background, 3D rendering, blue street sign
Ulcerative colitis is Zeposia's second US indication

Bristol Myers Squibb Company is moving into a new arena with the US approval of Zeposia (ozanimod) for ulcerative colitis, the company’s first approval in gastrointestinal disease. The company intends this approval – the second for the S1P modulator – to be the first of several in the GI space.

Zeposia, acquired in the $74bn buyout of Celgene Corporation, was initially approved by the US Food and Drug Administration...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

Pipeline Watch: ASCO Dominates Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By 

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By 

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By 

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

More from Scrip

Insmed’s PAH Data Indicate Potential To Surpass Established Therapies

 
• By 

Insmed’s inhaled treprostinil exceeded goals for reducing pulmonary vascular resistance and improving six-minute walk test distance in Phase IIb data.

NewAmsterdam’s CETP Inhibitor Improves Alzheimer’s Biomarkers

 
• By 

Data from the BROADWAY trial testing LDL-C reduction in adults with ASCVD showed that obicetrapib improved Alzheimer’s disease biomarkers, including tau and amyloid. Analysts think the data could differentiate obicetrapib against competitors in the cholesterol market.

With ACIP Upheaval, Merck & Co. Among Those Left In A Lurch

 

Merck’s newly approved Enflonsia for RSV is one of the products that was expected to be recommended for use by the CDC advisory committee in June.